ITPP
Myo-inositol trispyrophosphate · OXY111A · myo-inositol tripyrophosphate · ITPP hexasodium salt
Last updated
At a glance
Overview
Why ITPP Has a Niche in the Bodybuilding and Looksmaxxing Toolkit#
ITPP (myo-inositol trispyrophosphate, also known as OXY111A) is one of the more mechanistically elegant compounds in the endurance-and-conditioning corner of the research-chemical world. It is a membrane-permeant allosteric effector of hemoglobin — it loads into red blood cells, binds the 2,3-BPG site on deoxy-Hb, and right-shifts the oxygen dissociation curve so that more O₂ is offloaded at any given tissue pO₂. The effect rides on the lifespan of the loaded RBC pool, which is why a single administration delivers a functional window of roughly 5–12 days.
The community gravitates toward ITPP for three reasons: endurance and conditioning gains during hard cuts, cardio rescue on high-hematocrit AAS protocols where O₂ delivery feels sluggish despite a thick blood count, and a clean cognitive-alertness effect at smaller oral doses. None of this requires raising hematocrit, EPO, or red cell mass — ITPP changes how efficiently the existing blood pool unloads oxygen rather than adding more carrier.
"Modulation of the hemoglobin oxygen-binding curve by ITPP results in improved oxygen delivery to tissues while avoiding an increase in hematocrit or blood viscosity." — Oknińska et al., Biomedicine & Pharmacotherapy (2022)
The sections below cover documented ITPP dosing ranges, the oral-vs-injectable trade-off, the 5–7 day re-dose cadence dictated by RBC loading kinetics, stacking patterns with telmisartan and tadalafil on cycle, and the hard caveats — WADA detection, pulmonary right-shift in compromised subjects, and the orders-of-magnitude gap between rodent and community dose ranges.
How ITPP works
ITPP is not a hormone, not a receptor agonist, and not a metabolic substrate. It is an allosteric effector of hemoglobin — a small, highly charged molecule that loads into red blood cells and changes how readily Hb gives up its oxygen at the tissue. Every downstream effect (endurance, on-cycle cardio relief, the anti-tumor work in the OXY111A program, the reported alertness) traces back to that single biophysical event.
Allosteric Binding at the 2,3-BPG Site#
Inside every red blood cell, deoxygenated hemoglobin has a central cavity that normally binds 2,3-bisphosphoglycerate (2,3-BPG), the body's endogenous regulator of O₂ affinity. ITPP — with its six negative charges and three pyrophosphate bridges — outcompetes 2,3-BPG for that site and binds with far higher avidity. Once bound, it locks Hb into the T (tense, low-affinity) state, the conformation that prefers to release O₂ rather than hold it.
"ITPP enters red blood cells, binds at the 2,3-BPG site of deoxy-haemoglobin, and shifts the oxygen dissociation curve to the right, thereby promoting oxygen release in tissues." — Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C, Bioorganic & Medicinal Chemistry Letters (2005)
Practically: at any given tissue pO₂, a higher fraction of bound O₂ comes off the hemoglobin and into the working muscle, brain, or tumor bed. This is the right-shift of the oxyhemoglobin dissociation curve, quantified as an increase in p50 (the pO₂ at which Hb is 50% saturated). Rodent data shows p50 increases of ~22% at 1 g/kg and ~37% at 2 g/kg i.p.
Membrane Permeation — Why ITPP Works Where IP6 Doesn't#
This is the design trick that makes ITPP useful at all. Inositol hexakisphosphate (IP6, phytic acid) binds Hb beautifully in vitro, but it carries eight fixed negative charges and cannot cross the erythrocyte membrane without electroporation. ITPP's pyrophosphate bridges reduce the net charge density enough to allow passage through the band 3 anion exchanger, the same channel that handles bicarbonate/chloride exchange in red cells.
"ITPP, in contrast to other inositol phosphates, is both highly active and membrane-permeant due to its specific pyrophosphate bridges, enabling efficient erythrocyte loading." — Duarte CD, Greferath R, Nicolau C, Lehn JM, ChemBioChem (2010)
This is also why the functional half-life is days, not minutes. Plasma ITPP is cleared renally within hours, but the fraction that loaded into RBCs stays bound to Hb and circulates for the lifespan of those cells — full effect at ~48h, ~50% decay by day 5, washout by ~12 days. The dosing cadence (every 5–7 days) follows directly from this biology. The supplement community pitfall of daily dosing is wasted material; the RBC pool is already saturated.
Improved Tissue O₂ Extraction Without Raising Hematocrit#
This is the mechanistic point that makes ITPP interesting alongside heavy AAS protocols. EPO, blood doping, and high-aromatizing testosterone protocols all raise endurance by increasing red cell mass — more carrying capacity, but at the cost of viscosity, blood pressure, and stroke/PE risk. ITPP works on the opposite lever: same number of red cells, same Hb concentration, but each gram of Hb gives up more of its O₂ per pass through the capillary bed.
"Modulation of the hemoglobin oxygen-binding curve by ITPP results in improved oxygen delivery to tissues while avoiding an increase in hematocrit or blood viscosity." — Oknińska M, Mackiewicz U, Zajda K, Kieda C, Mączewski M, Biomedicine & Pharmacotherapy (2022)
For users running trenbolone, EQ, or high-dose testosterone with hematocrit pushing 53–55%, the cardio limitation is rarely "not enough red cells" — it's sluggish O₂ offloading and a left-shifted dissociation curve under those conditions. ITPP addresses that directly. It is not a substitute for phlebotomy or BP control, but it works on a different axis than either.
HIF-1α Suppression and the Hypoxia Axis#
Because tissues are getting more O₂ per cardiac output, the hypoxia-inducible factor 1α (HIF-1α) signaling pathway gets dialed down. HIF-1α is the master sensor of cellular hypoxia — it drives EPO transcription, VEGF release, and a large slate of anaerobic-metabolism genes. Chronic upregulation is a feature of failing myocardium, solid tumors, and untreated sleep apnea.
"These results provide evidence that ITPP enhances exercise capacity in both healthy and heart failure mice through increased oxygen delivery and suppressed HIF-1α signaling." — Biolo A, Greferath R, Siwik DA, Qin F, Valsky E, Fylaktakidou KC, Pothukanuri S, Duarte CD, Schwarz RP, Lehn JM, Nicolau C, Colucci WS, Proceedings of the National Academy of Sciences USA (2009)
In the same study, oral and i.p. ITPP improved time-to-exhaustion by +57% in healthy mice and +63% in heart-failure mice, with the oral arm still producing a +34% gain despite lower bioavailability. The HIF-1α suppression is the molecular fingerprint that the tissue actually received more oxygen — not just a hemodynamic curiosity.
Endothelial PTEN Activation — The Vascular Side Effect#
A second, less-discussed mechanism: ITPP activates PTEN in endothelial cells, normalizing pathological vasculature. This is the basis for the OXY111A oncology program (tumor vessels are chaotic and leaky; PTEN activation makes them behave more like normal vessels, which improves both drug delivery and the tumor's exposure to immune cells). For a physique-focused user, this arm is more curiosity than core mechanism — but it does suggest the molecule has biology beyond Hb that's worth keeping an eye on as the clinical program matures.
What This Means in Practice#
| Mechanism | Practical outcome |
|---|---|
| Right-shift of Hb dissociation curve | More O₂ delivered per heartbeat to working muscle and brain |
| Long RBC-bound functional half-life | Weekly (5–7 day) dosing cadence; daily dosing is wasted |
| No change in hematocrit | Stackable with high-Hct AAS without compounding viscosity risk |
| HIF-1α suppression | Reduced chronic hypoxia signaling; better conditioning under load |
| Pulmonary uptake trade-off | The same right-shift hurts O₂ loading when SpO₂ is already low — hard contraindication for untreated sleep apnea and significant pulmonary disease |
The mechanism is unusually clean for a research compound: one binding site, one biophysical effect, one downstream cascade. The open question is not whether it works in principle, but whether gram-scale oral doses in humans produce a p50 shift large enough to matter — published human p50 data at community doses simply doesn't exist yet.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 1000–2000 mg | Weekly | Documented entry-level range |
| Mid | 2000–4000 mg | Weekly | Most commonly studied range |
| High | 4000–8000 mg | Weekly | Functional effect tracks the loaded RBC pool — full effect ~48h, ~50% decay by day 5, washout by ~12 days. Re-dose every 5–7 days; stacking doses inside that window is redundant. |
Cycle length & outcomes
Documented cycle
2–12 weeks
Plateau after
12 wks
Cycle Notes#
ITPP doesn't cycle like an anabolic. There's no receptor downregulation, no HPTA suppression, no escalating tolerance — the effect rides entirely on the loaded RBC pool, and once a dose is administered the right-shift persists for the functional lifespan of those erythrocytes. The protocol is built around that PK, not around weeks-on / weeks-off conventions.
ITPP Dosage by Goal#
| Goal | Protocol Length | Per-Dose (Oral) | Frequency |
|---|---|---|---|
| Nootropic / on-demand alertness | As-needed | 500–1,500 mg | Single use or every 5–7 days |
| Endurance / conditioning block | 4–8 weeks | 2,000–3,000 mg | Every 5–7 days |
| On-cycle cardio rescue (high-Hct AAS) | 8–12 weeks | 3,000–5,000 mg | Every 5–7 days |
| Altitude / hypoxic-training adjunct | 1–3 weeks | 1,000–2,000 mg | 24–48h pre-exposure, then every 5–7 days |
| Aggressive endurance experimentation | 4–8 weeks | 5,000–8,000 mg | Every 5–7 days |
These are community-empirical ranges. There is no validated human exercise-physiology trial at gram-scale oral dosing, and the rodent literature used per-kg doses that would be absurd to scale linearly. Treat 1–5 g as the realistic working window; doses above 5 g escalate GI distress faster than they escalate effect.
Onset and Functional Half-Life#
"These results provide evidence that ITPP enhances exercise capacity in both healthy and heart failure mice through increased oxygen delivery and suppressed HIF-1α signaling." — Biolo et al., PNAS (2009)
The pharmacodynamic curve is the unusual part. Plasma half-life is short — the molecule is a hexa-anion cleared rapidly by the kidneys — but once ITPP crosses the erythrocyte membrane and binds Hb at the 2,3-BPG site, the right-shift travels with the red cell.
- Peak effect: ~24–48 hours post-dose
- ~50% decay: day 5
- Functional washout: ~10–12 days
"ITPP enters red blood cells, binds at the 2,3-BPG site of deoxy-haemoglobin, and shifts the oxygen dissociation curve to the right, thereby promoting oxygen release in tissues." — Fylaktakidou et al., Bioorg Med Chem Lett (2005)
This is why stacking doses inside a 5-day window is wasted material. The Hb pool is already loaded. Re-dosing every 5–7 days maintains a near-continuous right-shift; re-dosing every 3 days just costs money.
Loading and Tapering#
Neither is necessary. There is no loading phase — a single dose produces full p50 displacement within 48 hours, and the membrane-permeant pyrophosphate design (Duarte et al., 2010) means RBC loading is not dose-rate-limited the way IP6 would be.
There is no taper at the end of a block. ITPP is non-hormonal, has no rebound mechanism, and clears passively as the loaded erythrocyte cohort ages out. Stop dosing and the effect fades over ~10–12 days.
Cycle Length#
Because there's no receptor adaptation, "cycle length" really means "how long the use-case persists." The community ceiling sits around 12 weeks of continuous weekly dosing, mostly for pragmatic reasons:
- 2–4 weeks: altitude camps, short conditioning push, or one-off nootropic trials
- 4–8 weeks: dedicated endurance / conditioning block alongside a cut
- 8–12 weeks: on-cycle cardio support paired with a heavy AAS protocol where dyspnea is the limiting factor
Beyond 12 weeks of continuous gram-scale oral dosing, mineral chelation and renal-clearance considerations dominate, and there's no published data to lean on. Break for 4–6 weeks, reassess, then re-run if needed.
Bloodwork Cadence#
ITPP isn't hormonal, so the standard AAS panel is irrelevant to the compound itself. The monitoring that matters tracks oxygen physiology and clearance:
| Marker | Cadence | Why |
|---|---|---|
| CBC (hematocrit, hemoglobin, RBC) | Every 8–12 weeks | ITPP does not raise Hct, but co-administered AAS often does — and right-shift compounds the picture |
| Resting + post-exertion SpO₂ | Monthly during active use | Excessive pulmonary right-shift shows up here first |
| BMP / renal panel | Every 8–12 weeks | Renal clearance burden from chronic gram-scale dosing |
| Mineral panel (Ca, Mg, Zn, ferritin) | Every 12–16 weeks | Polyphosphate inositol chelation profile |
"Modulation of the hemoglobin oxygen-binding curve by ITPP results in improved oxygen delivery to tissues while avoiding an increase in hematocrit or blood viscosity." — Oknińska et al., Biomed Pharmacother (2022)
This is the relevant distinction from EPO or blood doping: ITPP changes Hb behavior, not red cell mass. The two strategies stack mechanistically but stack risk too, and the community consensus is to pick one.
Onset Timing in Practice#
Realistic expectation curve for an oral 2–4 g protocol:
- Days 1–2: Subjective alertness, sometimes a mild "easier breathing" sensation. Some users notice this within hours; others not at all.
- Days 2–5: Peak window for cardio sessions, conditioning work, or altitude exposure. This is where the published 34–57% time-to-exhaustion gain in rodents would, if it translates, be most evident.
- Days 5–7: Tapering benefit. Re-dose around day 5–6 to maintain continuity.
- Days 10–12: Functional washout if no re-dose.
Competition Timing#
"ITPP was detectable at low nanogram-per-milliliter concentrations for several days after administration, supporting its inclusion on the WADA banned list." — Görgens et al., Drug Test Anal (2014)
ITPP sits on the WADA Prohibited List and is detectable in urine at low ng/mL concentrations for days post-dose. Anyone competing in a tested federation should treat this as a non-starter. For untested contexts, the detection window is not the bottleneck — the use case is.
Risks & mistakes
Common (most users)#
- GI distress at gram-scale oral doses — nausea, acidic burn, loose stools. ITPP hexasodium salt is strongly acidic in solution; dissolving in 200–300 mL water with citrate buffering or juice, and pairing administration with food, largely eliminates this. Splitting a 4–6 g dose across two servings 2–3 hours apart is the standard fix.
- Mild transient flushing or warmth after dosing — consistent with improved peripheral O₂ offloading. Self-resolving; no mitigation needed.
- "Air hunger" during heavy efforts in the first 24–48 h — the right-shift means the body extracts more O₂ per breath, which can feel like sharper ventilatory drive on hard intervals. Reduces with familiarity; not a sign to back off the dose.
- Off taste / poor palatability — masked by acidic fruit juice (orange, grapefruit) which also helps with the buffering issue.
Uncommon (dose-dependent or individual)#
- Resting SpO₂ drift downward by 1–3% at higher oral doses (5+ g) — mechanistically expected, since pulmonary loading is the price of tissue offloading. A finger pulse oximeter is the cheapest monitoring tool. If resting SpO₂ drops below ~95% in an otherwise healthy subject, back the dose off.
- Headache or pressure sensation at higher doses — likely cerebrovascular flow / O₂-extraction shift. Reduce the next dose by 30–50% and re-dose no sooner than 7 days out.
- Mineral depletion with chronic high-gram dosing — polyphosphate inositols chelate Ca²⁺, Mg²⁺, Zn²⁺ and Fe²⁺. Anyone running 3+ g weekly across multiple months should pull a mineral panel (Ca, Mg, Zn, ferritin) at the 8–12 week mark and supplement accordingly.
- Renal load — clearance is renal and the molecule is excreted largely intact. A BMP every 8–12 weeks during extended use is appropriate, especially when stacked with NSAIDs, oral AAS, or other renally-cleared compounds.
- No documented effect on blood pressure or contractility in the rodent dose range, but the literature in humans is thin enough that quarterly BP checks are reasonable on extended protocols.
"Modulation of the hemoglobin oxygen-binding curve by ITPP results in improved oxygen delivery to tissues while avoiding an increase in hematocrit or blood viscosity." — Oknińska et al., Biomed Pharmacother (2022)
Rare but serious#
- Symptomatic hypoxemia in subjects with undiagnosed pulmonary disease or sleep apnea — the right-shift that helps tissue offloading hurts pulmonary uptake when arterial SpO₂ is already compromised. Warning signs: morning headaches, exertional dyspnea disproportionate to fitness, resting SpO₂ <93%. Discontinue and rule out underlying pulmonary or sleep pathology.
- Compounded cardiovascular load when stacked with EPO, blood doping, or untreated high-hematocrit AAS protocols — combining ITPP with strategies that raise red cell mass stacks two distinct mechanisms onto an already-thickened blood profile. No human data supports this combination.
- Worsening of tissue ischemia in subjects with active malignancy under treatment — ITPP's PTEN/anti-angiogenic arm is the subject of an ongoing oncology program (OXY111A); the interaction with cytotoxic chemotherapy, anti-VEGF agents, and radiotherapy is not established outside that clinical setting. Discontinue if a new oncology diagnosis emerges mid-protocol.
"These results provide evidence that ITPP enhances exercise capacity in both healthy and heart failure mice through increased oxygen delivery and suppressed HIF-1α signaling." — Biolo et al., PNAS (2009)
Hard contraindications#
- WADA-tested competition. ITPP is explicitly on the WADA prohibited list and detectable in urine at low ng/mL for days post-administration. Competing athletes in tested federations do not run this compound — period.
- Significant pulmonary disease (moderate-to-severe COPD, pulmonary fibrosis, pulmonary hypertension). The pulmonary cost of the right-shift is not acceptable in a lung already operating at reduced capacity.
- Untreated obstructive sleep apnea. Same logic — nocturnal desaturation events get worse, not better, with a right-shifted dissociation curve. Get the CPAP titration first.
- Renal impairment (eGFR <60 or known CKD). Clearance is renal and intact; accumulation risk is real.
- Active malignancy under cytotoxic, anti-angiogenic, or radiation treatment — outside an actual OXY111A clinical trial. The mechanism interacts with tumor vasculature and HIF signaling, and that interaction belongs in a trial protocol, not a recomp block.
- Concurrent EPO or autologous blood doping. The cardiovascular risk profile is not characterized and the published rationale does not support stacking.
"ITPP was detectable at low nanogram-per-milliliter concentrations for several days after administration, supporting its inclusion on the WADA banned list." — Görgens et al., Drug Test Anal (2014)
Gender, PCT, and ancillary considerations#
ITPP is non-hormonal. It does not bind androgen, estrogen, or progesterone receptors; it does not interact with the HPTA; it does not aromatize. PCT is not applicable. The same Hb-loading biology applies across the subject pool with no sex-specific contraindication identified in the literature — women running endurance or on-cycle cardio protocols do not face virilization, menstrual disruption, or fertility concerns from ITPP itself. Pregnancy and lactation have not been studied and fall outside the documented use case.
No ancillaries are pharmacologically required. In high-hematocrit AAS contexts where ITPP is layered onto a heavy oral or trenbolone protocol, the standard cardio-protective stack (telmisartan, low-dose tadalafil, periodic phlebotomy) is paired with it — but those ancillaries serve the AAS, not the ITPP. The most useful "ancillary" to ITPP itself is a $20 pulse oximeter and a quarterly CBC/BMP.
FAQ — ITPP
Research & citations
5 studies cited on this page.
Conclusion
ITPP is a niche but well-theorized hemoglobin modulator with real appeal for endurance, cardio rescue, and hypoxia-related applications — provided the limitations are understood.
Key takeaways:
- Typical oral dose: 2–5 g per administration, re-dosed every 5–7 days (single weekly loading matches RBC-bound effect window)
- Oral is the preferred route; solution is acidic, so buffering or co-administering with food is common to reduce GI upset
- Cycle length: 2–12 weeks; stacking doses within a 1-week window is redundant due to functional RBC loading
- Main stack synergy: telmisartan and low-dose tadalafil for cardio and hematocrit support during high-AAS cycles; phlebotomy if hematocrit is elevated
- Headline benefit: improved oxygen offloading and exercise capacity via right-shifted oxyhemoglobin dissociation — especially valuable for physique-focused users struggling with cardio or under high hematocrit
- Hard contraindications: WADA-tested athletes, unresolved hypoxemia, active malignancy under treatment
While clinical data in humans is pending, the mechanism and rodent results are robust. For research scenarios targeting endurance, tissue oxygenation, or on-cycle cardio, ITPP stands out as a mechanistically clean adjunct — best treated as a once-weekly protocol, not a daily staple.